155 related articles for article (PubMed ID: 38746541)
21. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
22. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
23. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
24. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
[TBL] [Abstract][Full Text] [Related]
26. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
27. [Problems in diagnosis and therapy of malignant pleural mesothelioma].
Türler A; Mönig SP; Raab M
Med Klin (Munich); 1997 Feb; 92(2):101-5. PubMed ID: 9139208
[TBL] [Abstract][Full Text] [Related]
28. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.
Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S
Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
30. Benign and malignant pleural effusions in former Wittenoom crocidolite millers and miners.
Cookson WO; De Klerk NH; Musk AW; Glancy JJ; Armstrong BK; Hobbs MS
Aust N Z J Med; 1985 Dec; 15(6):731-7. PubMed ID: 3010925
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis and treatment of malignant pleural mesothelioma.
Rodríguez Panadero F
Arch Bronconeumol; 2015 Apr; 51(4):177-84. PubMed ID: 25059587
[TBL] [Abstract][Full Text] [Related]
32. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
Attanoos RL; Gibbs AR
Histopathology; 2008 Sep; 53(3):340-4. PubMed ID: 18647189
[TBL] [Abstract][Full Text] [Related]
33. [Thoracoscopy in pleural mesothelioma].
Zhang DH; Gu YT; Pan WS
Zhonghua Jie He He Hu Xi Za Zhi; 1993 Jun; 16(3):150-3, 187. PubMed ID: 8242812
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of histologic subtyping of malignant pleural mesothelioma.
Brcic L; Kern I
Transl Lung Cancer Res; 2020 Jun; 9(3):924-933. PubMed ID: 32676358
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Kobashi Y; Matsushima T; Irei T
Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
[TBL] [Abstract][Full Text] [Related]
36. [Death certification of pleural malignant mesothelioma from the Italian National Institute of Statistics: a comparison on 269 clinical diagnosis confirmed at autopsy (1997-2016)].
Barbieri PG; Finotto L; Belli S; Festa R; Comba P
Epidemiol Prev; 2021; 45(3):149-154. PubMed ID: 34212695
[TBL] [Abstract][Full Text] [Related]
37. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
38. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC; Tsim S; Kanellakis N; Ball H; Talbot DC; Blyth KG; Maskell NA; Psallidas I
Eur Respir Rev; 2016 Dec; 25(142):472-486. PubMed ID: 27903668
[TBL] [Abstract][Full Text] [Related]
39. Stereological evaluation of malignant mesothelioma versus benign pleural hyperplasia.
Bogers J; Jacobs W; Segers K; Van Daele A; Weyler J; Van Marck E
Pathol Res Pract; 1996 Jan; 192(1):10-4. PubMed ID: 8685035
[TBL] [Abstract][Full Text] [Related]
40. Malignant pleural mesothelioma with heterologous elements.
Kawai T; Seki R; Miyajima K; Nakashima H; Takeda T; Murakami T; Aoe K; Okabe K; Homma K; Tsukamoto Y; Sunada K; Terasaki Y; Iida M; Orikasa H; Hiroshima K
J Clin Pathol; 2021 Aug; ():. PubMed ID: 34376566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
